

truncated RANTES polypeptide lacks NH₂-terminal amino acid residues 1-2 and has chemokine antagonistic activity.

28. (New) An isolated amino-terminally truncated RANTES comprising residues 4-68 of a RANTES polypeptide according to RANTES (SEQ ID NO: 2), wherein the truncated RANTES polypeptide lacks NH₂-terminal amino acid residues 1-3 and has chemokine antagonistic activity.
29. (New) An isolated amino-terminally truncated RANTES comprising residues 5-68 of an RANTES polypeptide according to SEQ ID NO: 2, wherein the truncated RANTES polypeptide lacks NH₂-terminal amino acid residues 1-4 and has chemokine antagonistic activity.
30. (New) The isolated amino-terminally truncated RANTES of claims 26-29, wherein the truncated RANTES polypeptide is in glycosylated form.
31. (New) A pharmaceutical composition comprising an isolated truncated RANTES polypeptide according to any one of claims 25-29, wherein the composition comprises one or more pharmaceutically acceptable carriers and/or excipients.
32. (New) The pharmaceutical composition according to claim 31, wherein the isolated truncated RANTES polypeptide is in glycosylated form.

RESPONSE

Pending claims